BR112015014855A2 - compostos radiossensibilizadores para uso em combinação com radiação - Google Patents
compostos radiossensibilizadores para uso em combinação com radiaçãoInfo
- Publication number
- BR112015014855A2 BR112015014855A2 BR112015014855A BR112015014855A BR112015014855A2 BR 112015014855 A2 BR112015014855 A2 BR 112015014855A2 BR 112015014855 A BR112015014855 A BR 112015014855A BR 112015014855 A BR112015014855 A BR 112015014855A BR 112015014855 A2 BR112015014855 A2 BR 112015014855A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- compounds
- radiosensitizing
- radiosensitizing compounds
- radiation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000000637 radiosensitizating effect Effects 0.000 title abstract 4
- 230000005855 radiation Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 230000027756 respiratory electron transport chain Effects 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/52—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261797983P | 2012-12-20 | 2012-12-20 | |
| PCT/CA2013/051005 WO2014094178A1 (en) | 2012-12-20 | 2013-12-20 | Radiosensitizer compounds for use in combination with radiation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015014855A2 true BR112015014855A2 (pt) | 2017-07-11 |
Family
ID=50977492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015014855A BR112015014855A2 (pt) | 2012-12-20 | 2013-12-20 | compostos radiossensibilizadores para uso em combinação com radiação |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9655965B2 (enExample) |
| EP (1) | EP2935215B1 (enExample) |
| JP (1) | JP6321673B2 (enExample) |
| KR (1) | KR102278760B1 (enExample) |
| CN (1) | CN105164107B (enExample) |
| AU (1) | AU2013362757B2 (enExample) |
| BR (1) | BR112015014855A2 (enExample) |
| CA (1) | CA2895526C (enExample) |
| MX (1) | MX2015008010A (enExample) |
| WO (1) | WO2014094178A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014334461B2 (en) * | 2013-10-08 | 2019-06-13 | Qing-bin LU | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy |
| PL3277284T3 (pl) * | 2015-04-02 | 2021-03-08 | Proximagen, Llc | Nowe terapie nowotworu |
| CN106045932B (zh) * | 2016-06-06 | 2018-05-15 | 浙江省肿瘤医院 | 一种具有放射增敏作用的化合物及其应用 |
| JP6955243B2 (ja) * | 2017-02-24 | 2021-10-27 | 学校法人北里研究所 | ネクローシスの検出キット及びその使用 |
| KR102263216B1 (ko) * | 2018-05-30 | 2021-06-14 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물의 방사선 치료 증진 용도 |
| WO2021224186A1 (en) * | 2020-05-04 | 2021-11-11 | Institut Curie | New pyridine derivatives as radiosensitizers |
| CN114478524A (zh) * | 2022-03-15 | 2022-05-13 | 江苏省肿瘤医院 | 1,8-萘啶类化合物及其应用 |
| CN114560799A (zh) * | 2022-03-15 | 2022-05-31 | 江苏省肿瘤医院 | 腈基取代苯基类化合物及其应用 |
| CN120501862B (zh) * | 2025-07-18 | 2025-10-10 | 四川大学华西医院 | 一种能够放射增敏和防护放射性损伤的双效化合物、包含其的组合物及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5011451B1 (enExample) * | 1969-05-05 | 1975-05-01 | ||
| CH559729A5 (enExample) * | 1970-10-23 | 1975-03-14 | Hoechst Ag | |
| US3822261A (en) * | 1972-10-30 | 1974-07-02 | Dow Chemical Co | 5,6-dihalo-2-fluoroalkyl-1h-imidazo(4,5-b)pyrazines |
| GR72941B (enExample) * | 1978-10-20 | 1984-01-16 | Lilly Co Eli | |
| US4210647A (en) * | 1979-06-18 | 1980-07-01 | Eli Lilly And Company | Antiviral combinations |
| JPS597175A (ja) * | 1982-07-01 | 1984-01-14 | メルク・エンド・カムパニ−・インコ−ポレ−テツド | 放射線治療用添加剤として有用な、クロロニトロアミノピラジン及びアルキルアミノピラジンのアミノとアミド誘導体 |
| GB8722488D0 (en) * | 1987-09-24 | 1987-10-28 | Fujisawa Pharmaceutical Co | Imidazopyridine compound |
| WO1994000124A1 (en) * | 1992-06-22 | 1994-01-06 | Eckard Weber | Glycine receptor antagonists and the use thereof |
| EP0743855A1 (en) * | 1994-01-03 | 1996-11-27 | Acea Pharmaceuticals, Inc. | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor |
| US5753687A (en) * | 1995-06-19 | 1998-05-19 | Ontogen Corporation | Modulators of proteins with phosphotryrosine recognition units |
| CA2397665A1 (en) * | 2000-01-24 | 2001-07-26 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| US6538010B1 (en) * | 2000-11-08 | 2003-03-25 | Research Triangle Institute | Compounds and methods for promoting smoking cessation |
| GB0428082D0 (en) * | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| US20090137640A1 (en) * | 2005-04-01 | 2009-05-28 | Taiho Pharmaceutical Co.Ltd | Potentiator for radiation therapy comprising pyridine derivative as active ingredient |
| CN101155782B (zh) * | 2005-04-01 | 2011-05-04 | 大鹏药品工业株式会社 | 以吡啶衍生物为有效成分的放射线治疗增强剂 |
| WO2008021851A2 (en) * | 2006-08-09 | 2008-02-21 | Smithkline Beecham Corporation | Novel compounds as antagonists or inverse agonists for opioid receptors |
| WO2008042282A2 (en) * | 2006-09-28 | 2008-04-10 | Exelixis, Inc. | Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators |
| JP5178738B2 (ja) * | 2006-12-20 | 2013-04-10 | メルク・シャープ・アンド・ドーム・コーポレーション | 新規なｊｎｋ阻害剤 |
| MX2011004953A (es) * | 2008-11-10 | 2011-12-14 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
| WO2011026219A1 (en) * | 2009-09-01 | 2011-03-10 | Lu qing-bin | Combination therapy for cancer comprising a platinum -based antineoplastic agent and a biocompatible electron donor |
| EP2569289A1 (en) * | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
| GB201017345D0 (en) * | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
-
2013
- 2013-12-20 BR BR112015014855A patent/BR112015014855A2/pt not_active Application Discontinuation
- 2013-12-20 US US14/654,165 patent/US9655965B2/en not_active Expired - Fee Related
- 2013-12-20 KR KR1020157019682A patent/KR102278760B1/ko not_active Expired - Fee Related
- 2013-12-20 WO PCT/CA2013/051005 patent/WO2014094178A1/en not_active Ceased
- 2013-12-20 CA CA2895526A patent/CA2895526C/en active Active
- 2013-12-20 MX MX2015008010A patent/MX2015008010A/es unknown
- 2013-12-20 CN CN201380073147.7A patent/CN105164107B/zh not_active Expired - Fee Related
- 2013-12-20 JP JP2015548130A patent/JP6321673B2/ja not_active Expired - Fee Related
- 2013-12-20 AU AU2013362757A patent/AU2013362757B2/en not_active Ceased
- 2013-12-20 EP EP13865418.1A patent/EP2935215B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2935215B1 (en) | 2019-11-13 |
| CN105164107B (zh) | 2017-12-05 |
| AU2013362757B2 (en) | 2018-06-14 |
| JP2016504325A (ja) | 2016-02-12 |
| CA2895526A1 (en) | 2014-06-26 |
| AU2013362757A1 (en) | 2015-07-30 |
| KR102278760B1 (ko) | 2021-07-20 |
| US20150343059A1 (en) | 2015-12-03 |
| JP6321673B2 (ja) | 2018-05-09 |
| MX2015008010A (es) | 2016-04-26 |
| EP2935215A4 (en) | 2016-10-26 |
| EP2935215A1 (en) | 2015-10-28 |
| WO2014094178A1 (en) | 2014-06-26 |
| CA2895526C (en) | 2021-08-24 |
| US9655965B2 (en) | 2017-05-23 |
| KR20150120953A (ko) | 2015-10-28 |
| CN105164107A (zh) | 2015-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015014855A2 (pt) | compostos radiossensibilizadores para uso em combinação com radiação | |
| BR112015023060A2 (pt) | entidades químicas | |
| BR112021022897A2 (pt) | Inibidor contendo derivado bicíclico, método de preparação do mesmo e uso do mesmo | |
| BR112021026498A2 (pt) | Composto, uso do composto e composição farmacêutica | |
| BR112015027951A8 (pt) | arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| UY33440A (es) | ?compuestos pirimidinílicos para uso como inhibidores de atr?. | |
| BR112015011148A8 (pt) | composto, composição farmacêutica, e combinação | |
| ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
| CL2012001422A1 (es) | Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| BR112012013508A2 (pt) | pirazolopirimidinas e heterociclos relacionados como inibidores de ck2 | |
| BR112015021115A2 (pt) | agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes | |
| BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
| BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
| BR112015011147A2 (pt) | composto, composição farmacêutica, e, métodos para tratamento de uma doença e de uma condição | |
| BR112014024672A8 (pt) | Composições farmacêuticas para terapia de combinação | |
| BR112015011298A2 (pt) | inibidores de cotransportador 1 de glicose de sódio | |
| CL2014001547A1 (es) | Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales. | |
| CR11199A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| EA201300211A1 (ru) | N-ацилсульфонамидные промоторы апоптоза | |
| BR112017004741A2 (pt) | compostos e composições como inibidores da raf quinase | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| BR112015014090A2 (pt) | intensificador de inibidores de zeste homólogo 2 | |
| BR112012011457A2 (pt) | uso antitumoral de cabazitaxel. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |